verapamil has been researched along with Hypertrophy, Left Ventricular in 28 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The regression of left ventricular hypertrophy in hypertensive patients was evaluated in a multicenter study with a combination therapy of verapamil 120 mg and captopril 25 mg given once or twice daily." | 9.08 | Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study. ( Brandt, D; Hofmann, R; Magometschnigg, D; Sihorsch, K; Stoschitzky, K; Zangeneh, M; Zenker, G, 1997) |
| "We evaluated whether verapamil (VERA) has a protective effect on left ventricular hypertrophy (LVH) induced by Isoproterenol (ISO) in rat." | 7.69 | [Effect of verapamil on left ventricular hypertrophy induced by isoproterenol]. ( Bombig, MT; Brandão, A; Costa, A; Costa, EA; Ferreira, C; Leite, DA; Luna Filho, B; Murad, N; Póvoa, R, 1996) |
| "Thirty-three hypertensive patients with left ventricular hypertrophy were treated with slow-release verapamil for 1 year." | 7.69 | [Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil]. ( Li, G; Sun, M; Zhou, H, 1997) |
| "In conclusion, the left ventricular hypertrophy and the significant decrease of the left ventricular cardiomyocyte number caused by the NO synthesis inhibition are efficiently prevented with the use of enalapril and verapamil." | 5.31 | The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition. ( Mandarim-De-Lacerda, CA; Pereira, LM, 2001) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "The regression of left ventricular hypertrophy in hypertensive patients was evaluated in a multicenter study with a combination therapy of verapamil 120 mg and captopril 25 mg given once or twice daily." | 5.08 | Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study. ( Brandt, D; Hofmann, R; Magometschnigg, D; Sihorsch, K; Stoschitzky, K; Zangeneh, M; Zenker, G, 1997) |
| " We therefore investigated the effects of diltiazem on cardiac gene expression in normotensive and hypertensive rats with left ventricular hypertrophy and compared the results with our previous findings on verapamil and nifedipine." | 3.83 | Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects. ( Borlak, J; Zwadlo, C, 2016) |
| "Contrast-enhanced magnetic resonance (MR) imaging was used to detect and quantify the extent of myocardial injury after a brief coronary occlusion and reperfusion in response to verapamil treatment in a rat model of left ventricular hypertrophy (LVH)." | 3.69 | Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging. ( Derugin, N; Higgins, CB; Lauerma, K; Saeed, M; Wendland, MF; Yu, KK, 1996) |
| "We evaluated whether verapamil (VERA) has a protective effect on left ventricular hypertrophy (LVH) induced by Isoproterenol (ISO) in rat." | 3.69 | [Effect of verapamil on left ventricular hypertrophy induced by isoproterenol]. ( Bombig, MT; Brandão, A; Costa, A; Costa, EA; Ferreira, C; Leite, DA; Luna Filho, B; Murad, N; Póvoa, R, 1996) |
| "Thirty-three hypertensive patients with left ventricular hypertrophy were treated with slow-release verapamil for 1 year." | 3.69 | [Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil]. ( Li, G; Sun, M; Zhou, H, 1997) |
| "We performed two sets of experiments in order to prevent or to regress cardiac and vascular hypertrophy, using antihypertensive and subantihypertensive doses of the angiotensin converting enzyme inhibitor zabicipril." | 3.68 | Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. ( Gohlke, P; Lamberty, V; Mall, G; Martorana, P; Mattfeld, T; Stoll, M; Unger, T; van Even, P, 1992) |
| "Left ventricular hypertrophy is very frequent when determined by echocardiography and all three drugs produced regression of left ventricular hypertrophy in a different way with respect to left ventricle geometry, an effect which could have potential therapeutic implications." | 2.68 | [Effect of 3 hypertensive++ agents on ventricular geometry and function]. ( Gómez Pajuelo, C; Gómez Sánchez, MA; Lombera Romero, F; Marín Ruiz, R; Sáenz de la Calzada, C; Sanz Julve, M; Tascón Pérez, J, 1995) |
| "It is now recognized that left ventricular hypertrophy (LVH), often associated with hypertension, is itself a risk factor for coronary disease in the elderly." | 2.67 | Left ventricular mass regression in elderly hypertensives. ( Gerstenblith, G, 1992) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| "In conclusion, the left ventricular hypertrophy and the significant decrease of the left ventricular cardiomyocyte number caused by the NO synthesis inhibition are efficiently prevented with the use of enalapril and verapamil." | 1.31 | The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition. ( Mandarim-De-Lacerda, CA; Pereira, LM, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (53.57) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| De Jong, HN | 1 |
| Dewey, FE | 1 |
| Cordero, P | 1 |
| Victorio, RA | 1 |
| Kirillova, A | 1 |
| Huang, Y | 1 |
| Madhvani, R | 1 |
| Seo, K | 1 |
| Werdich, AA | 1 |
| Lan, F | 1 |
| Orcholski, M | 1 |
| Liu, WR | 1 |
| Erbilgin, A | 1 |
| Wheeler, MT | 1 |
| Chen, R | 1 |
| Pan, S | 1 |
| Kim, YM | 1 |
| Bommakanti, K | 1 |
| Marcou, CA | 1 |
| Bos, JM | 1 |
| Haddad, F | 1 |
| Ackerman, M | 1 |
| Vasan, RS | 1 |
| MacRae, C | 1 |
| Wu, JC | 1 |
| de Jesus Perez, V | 1 |
| Snyder, M | 1 |
| Parikh, VN | 1 |
| Ashley, EA | 1 |
| Zwadlo, C | 1 |
| Borlak, J | 1 |
| Oghlakian, GO | 1 |
| Sipahi, I | 1 |
| Fang, JC | 1 |
| Iskenderov, BG | 2 |
| Burmistrova, LF | 2 |
| Vakina, TN | 1 |
| Lokhina, TV | 2 |
| Bogdanova, SR | 1 |
| Cooper-Dehoff, R | 1 |
| Cohen, JD | 1 |
| Bakris, GL | 1 |
| Messerli, FH | 1 |
| Erdine, S | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Pepine, CJ | 1 |
| Berenshteĭn, NV | 1 |
| Kokkinos, PF | 1 |
| Narayan, P | 1 |
| Colleran, JA | 1 |
| Pittaras, A | 1 |
| Notargiacomo, A | 1 |
| Reda, D | 1 |
| Papademetriou, V | 1 |
| Arita, M | 1 |
| Horinaka, S | 1 |
| Komatsu, K | 1 |
| Frohlich, ED | 1 |
| Gómez Pajuelo, C | 1 |
| Gómez Sánchez, MA | 1 |
| Marín Ruiz, R | 1 |
| Lombera Romero, F | 1 |
| Sanz Julve, M | 1 |
| Tascón Pérez, J | 1 |
| Sáenz de la Calzada, C | 1 |
| Suzuki, H | 1 |
| Schaefer, L | 1 |
| Ling, H | 1 |
| Schaefer, RM | 1 |
| Dämmrich, J | 1 |
| Teschner, M | 1 |
| Heidland, A | 1 |
| Sau, F | 1 |
| Seguro, C | 1 |
| Alvau, MD | 1 |
| Pargentino, E | 1 |
| Cherchi, A | 1 |
| Qian, XX | 1 |
| Chen, AH | 1 |
| Deng, JY | 1 |
| Tang, XM | 1 |
| Liu, YF | 1 |
| Li, ZL | 1 |
| Ou, SB | 1 |
| Wu, ZN | 1 |
| Wang, KR | 1 |
| Lauerma, K | 1 |
| Saeed, M | 1 |
| Wendland, MF | 1 |
| Derugin, N | 1 |
| Yu, KK | 1 |
| Higgins, CB | 1 |
| Bombig, MT | 1 |
| Luna Filho, B | 1 |
| Costa, EA | 1 |
| Leite, DA | 1 |
| Póvoa, R | 1 |
| Murad, N | 1 |
| Costa, A | 1 |
| Brandão, A | 1 |
| Ferreira, C | 1 |
| Magometschnigg, D | 1 |
| Brandt, D | 1 |
| Hofmann, R | 1 |
| Sihorsch, K | 1 |
| Stoschitzky, K | 1 |
| Zangeneh, M | 1 |
| Zenker, G | 1 |
| Li, G | 1 |
| Sun, M | 1 |
| Zhou, H | 1 |
| Sakurai, H | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Hattori, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Schussheim, AE | 1 |
| Diamond, JA | 1 |
| Phillips, RA | 1 |
| Sandmann, S | 1 |
| Claas, R | 1 |
| Cleutjens, JP | 1 |
| Daemen, MJ | 1 |
| Unger, T | 2 |
| Sareli, P | 2 |
| Radevski, IV | 1 |
| Valtchanova, ZP | 1 |
| Libhaber, E | 2 |
| Candy, GP | 1 |
| Den Hond, E | 1 |
| Libhaber, C | 1 |
| Skudicky, D | 2 |
| Wang, JG | 2 |
| Staessen, JA | 2 |
| Pereira, LM | 1 |
| Mandarim-De-Lacerda, CA | 1 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 1 |
| Barbagallo, M | 1 |
| Candy, G | 1 |
| Radevski, I | 1 |
| Valtchanova, Z | 1 |
| Tshele, E | 1 |
| Thijs, L | 1 |
| Gerstenblith, G | 1 |
| Velloso, LG | 1 |
| Santanna, AF | 1 |
| Barretto, AC | 1 |
| Gohlke, P | 1 |
| Stoll, M | 1 |
| Lamberty, V | 1 |
| Mattfeld, T | 1 |
| Mall, G | 1 |
| van Even, P | 1 |
| Martorana, P | 1 |
| Gosse, P | 1 |
| Roudaut, R | 1 |
| Dallocchio, M | 1 |
| Wheeldon, NM | 1 |
| Pringle, TH | 1 |
| Lipworth, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction[NCT03837470] | Early Phase 1 | 14 participants (Actual) | Interventional | 2019-05-06 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for verapamil and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2011 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
10 trials available for verapamil and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
Topics: Adult; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relation | 2007 |
Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Combined Modality Therapy; Exerc | 1995 |
[Effect of 3 hypertensive++ agents on ventricular geometry and function].
Topics: Atenolol; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Midd | 1995 |
Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Ch | 1997 |
Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black Pe | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Pressure; Body Mass Index; Calcium Cha | 2002 |
Left ventricular mass regression in elderly hypertensives.
Topics: Aging; Atenolol; Blood Pressure; Coronary Circulation; Delayed-Action Preparations; Echocardiography | 1992 |
[Effects of verapamil and nifedipine on blood pressure during rest and exertion and on left ventricular hypertrophy].
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Echocardiography, Doppler; Exercise Test; Female; | 1992 |
16 other studies available for verapamil and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy.
Topics: Animals; Calcium; Cardiomegaly; Cardiomyopathy, Hypertrophic; Co-Repressor Proteins; Cytoskeletal Pr | 2022 |
Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects.
Topics: Animals; Calcium Channel Blockers; Diltiazem; Gene Expression Profiling; Gene Expression Regulation; | 2016 |
[Efficacy of and tolerance to combined therapy with dihydropyridine and non-dihydropyridine Ca antagonists in patients with moderate arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dose-R | 2005 |
Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Celiprolol | 1993 |
Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases.
Topics: Animals; Cathepsin B; Cathepsin H; Cathepsin L; Cathepsins; Cysteine Endopeptidases; Enalapril; Endo | 1995 |
[Effects of verapamil on left ventricular mass and diastolic function in hypertensive patients].
Topics: Adult; Blood Pressure; Diastole; Echocardiography; Female; Heart Rate; Humans; Hypertension; Hypertr | 1993 |
The effect of Isoptin SR on blood pressure, heart function and hypertrophy of left ventricle of hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hypertension; Hypertrophy, | 1994 |
Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging.
Topics: Animals; Aorta, Abdominal; Calcium Channel Blockers; Coloring Agents; Contrast Media; Disease Models | 1996 |
[Effect of verapamil on left ventricular hypertrophy induced by isoproterenol].
Topics: Animals; Calcium Channel Blockers; Cardiotonic Agents; Collagen; Heart Ventricles; Hypertrophy, Left | 1996 |
[Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil].
Topics: Adult; Calcium Channel Blockers; Delayed-Action Preparations; Female; Humans; Hypertension; Hypertro | 1997 |
Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Echocardiogr | 2001 |
Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Heart Failure; Hemodynamics; Hypertrophy, Left Ventri | 2001 |
The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bl | 2001 |
[Tachycardiomyopathy induced by atrial fibrillation].
Topics: Atrial Fibrillation; Atrioventricular Node; Female; Heart Rate; Humans; Hypertrophy, Left Ventricula | 1992 |
Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Bridged Bicyclo Compounds; Brid | 1992 |
Obstructive left ventricular hypertrophy. Reversibility of outflow tract obstruction by drug therapy.
Topics: Aged; Aged, 80 and over; Atenolol; Echocardiography, Doppler; Female; Humans; Hypertrophy, Left Vent | 1992 |